Clinical trial · no report yet · Phase 1
NCT04161755
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
- NCT04161755 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Atezolizumab; RO7198457; mFOLFIRINOX
- Arms
- Pancreatic Cancer · Experimental
- Enrollment
- 29
- Primary outcomes
- Drug related toxicity
- Sponsor
- Memorial Sloan Kettering Cancer Center with Genentech, Inc., Massachusetts Institute of Technology
- Start
- Dec 13, 2019
- Primary completion
- Nov 11, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04161755 · updated Jan 7, 2026